Abstract
Emerging evidence indicates that the relationship between coronavirus disease 2019 (COVID-19) and diabetes is 2-fold: 1) it is known that the presence of diabetes and other metabolic alterations poses a considerably high risk to develop a severe COVID-19; 2) patients who survived a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk of developing new-onset diabetes. However, the mechanisms underlying this association are mostly unknown, and there are no reliable biomarkers to predict the development of new-onset diabetes. In the present study, we demonstrate that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells reliably predicts the risk of developing new-onset diabetes in COVID-19. This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer.
SIGNIFICANCE STATEMENT We demonstrate for the first time that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells is able to reliably predict the risk of developing diabetes after having contracted coronavirus disease 2019 (COVID-19). This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer. Our findings are also relevant when considering the emerging importance of post-acute sequelae of COVID-19, with systemic manifestations observed even months after viral negativization (long COVID).
Footnotes
- Received April 2, 2022.
- Accepted January 23, 2024.
Santulli’s Laboratory is supported in part by National Institutes of Health National Heart, Lung, and Blood Institute [Grant R01-HL159062], [Grant R01-HL146691], and [Grant T32-HL144456] and National Institute of Diabetes and Digestive and Kidney Diseases [Grant R01-DK123259] and [Grant R01-DK033823] (to G.S.), by the Diabetes Action Research and Education Foundation (to G.S.), by the Samuel Waxman Foundation (to G.S.), and by the Monique Weill-Caulier and Irma T. Hirschl Trusts (to G.S.). This publication was also produced with the cofunding of the European Union – Next Generation EU, in the context of The National Recovery and Resilience Plan, PE8 Investment, Project Age-It (Ageing Well in an Ageing Society) (to P.M.). S.S.J., J.G., U.K., and F.V. are supported in part by postdoctoral fellowships of the American Heart Association (AHA-836407, AHA-35211151, AHA-1026190, and AHA-241195524).
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
↵1P.M., S.S.J., and M.V.M. share the first authorship.
- Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
